News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Oct 25, 2005

  Insmed Receives European Orphan Drug Designation for SomatoKine for the Treatment of Extreme Insulin Resistance; Company to Initiate Clinial Trial in Type A Insulin Resistance
• Oct 25, 2005

  FDA to Review Insmed's Complete Response to Approvable Letter for iPlex
• Oct 24, 2005

  Insmed to Present at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference
• Oct 18, 2005

  Insmed to Present at the BIO Investor Forum Conference
• Oct 17, 2005

  Insmed Submits Response to FDA Approvable Letter for iPlex
• Sep 29, 2005

  Insmed Issues Statement Regarding IPLEX(TM) Approvable Letter Press Release
• Sep 29, 2005

  Insmed Provides Update on iPlex Pivotal Trial Data in Severe Primary IGF-1 Deficiency
• Sep 25, 2005

  Insmed Receives Approvable Letter for iPlex(TM); Conference Call Tomorrow at 8:00am EST
• Sep 24, 2005

  Insmed Announces Appointment of Dr. Kenneth Attie; Former Genentech Researcher Assumes Role as Medical Director
• Sep 19, 2005

  SomatoKine(R) Pivotal Data to Be Featured in a Podium Presentation at the ESPE/LWPES 7th Joint Meeting of Pediatric Endocriniology in Lyon, France
• Aug 8, 2005

  Insmed Incorporated Reports Financial Results for the Second Quarter and First Half of 2005
• Aug 2, 2005

  Insmed to Release Second Quarter Financial Results; Monday, August 8
• Jun 10, 2005

  FDA Extends PDUFA Date for SomatoKine to October 03, 2005
• May 31, 2005

  Insmed Reports Detailed Positive Results from Its Pivotal Clinical Trial of SomatoKine in Patients with Growth Hormone Insensitivity Syndrome
• May 25, 2005

  Insmed to Present at Needham & Company Biotechnology Conference May 26, 2005
• May 24, 2005

  Insmed Announces the Continuation of Litigation in the United Kingdom; Judge's Ruling Allows for the Continuation of Legal Action in Suit Filed by Tercica
• May 19, 2005

  Insmed to Present at UBS Global Pharmaceutical Conference May 23, 2005
• May 17, 2005

  Insmed Announces Exclusive Option Agreement with UCSF for Series of IGF-1 Receptor Antagonists; Agreement Expands Collaboration on IGF-1 Program in Prostate Cancer
• May 10, 2005

  Insmed Incorporated Reports Financial Results for First Quarter of 2005
• May 5, 2005

  Insmed Inc. to Webcast First Quarter Earnings Conference Call Thursday, May 12 at 8:30 a.m. (ET)
• Apr 26, 2005

  Insmed Initiates Phase II Trial With SomatoKine(R) in Type A Extreme Insulin Resistance
• Apr 20, 2005

  Insmed Initiates Phase II HIV-Associated Lipodystrophy Trial With Somatokine(R)
• Apr 18, 2005

  Patent Infringement Suit Against Insmed Dismissed
• Apr 13, 2005

  FDA Grants Priority Review for Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
• Mar 16, 2005

  Insmed Incorporated Reports Financial Results for Fourth Quarter and Twelve-Months of 2004

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download